Crescent Biopharma's top three insider shareholders as of September 09, 2026 are Public Equities, L.P. Invus (TenPercentOwner, 6.32Mn shares), Funds Management Llc Fairmount (Director, 3.60Mn shares), Edwin Rock (Chief Medical Officer, 680.40K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Public Equities, L.P. Invus | TenPercentOwner | 6,317,565 | 0 | 6,317,565 | 53.0% | 09 Aug, 2024 |
| 2 | Funds Management Llc Fairmount | Director, TenPercentOwner | 0 | 3,601,316 | 3,601,316 | 30.2% | 20 Jul, 2026 |
| 3 | Edwin Rock | Chief Medical Officer | 680,403 | 0 | 680,403 | 5.7% | 24 Jun, 2024 |
| 4 | John L. Magnani | Svp Of Research, Cso | 366,078 | 0 | 366,078 | 3.1% | 14 Nov, 2022 |
| 5 | Joshua T Brumm | Chief Executive Officer | 323,517 | 0 | 323,517 | 2.7% | 17 Dec, 2025 |
| 6 | Jonathan Mcneill | President And Coo | 139,158 | 0 | 139,158 | 1.2% | 23 Jun, 2026 |
| 7 | Bruce S Johnson | Svp Chief Commercial Officer | 138,980 | 0 | 138,980 | 1.2% | 09 May, 2023 |
| 8 | Brian M. Hahn | Svp Finance, Cfo | 70,643 | 0 | 70,643 | 0.6% | 20 Jun, 2024 |
| 9 | Partners L P/Il Bvf | TenPercentOwner | 62,383 | 0 | 62,383 | 0.5% | 17 Jun, 2025 |
| 10 | Christopher Grant Doughty | Chief Business Officer | 62,194 | 0 | 62,194 | 0.5% | 17 Dec, 2025 |
| 11 | Armand Girard | Svp, Chief Business Officer | 29,161 | 0 | 29,161 | 0.2% | 14 Nov, 2022 |
| 12 | Harout Semerjian | Chief Executive Officer | 25,000 | 0 | 25,000 | 0.2% | 14 Nov, 2022 |
| 13 | Jan Pinkas | Chief Scientific Officer | 22,239 | 0 | 22,239 | 0.2% | 23 Jun, 2026 |
| 14 | Ellie Eunkyung Im | Chief Medical Officer | 22,069 | 0 | 22,069 | 0.2% | 23 Jun, 2026 |
| 15 | Richard William Scalzo | Chief Financial Officer | 20,298 | 0 | 20,298 | 0.2% | 23 Jun, 2026 |
| 16 | Barbara Harlin Bispham | Officer | 19,330 | 0 | 19,330 | 0.2% | 23 Jun, 2026 |
| 17 | Ryan Lynch | Officer | 13,871 | 0 | 13,871 | 0.1% | 23 Jun, 2026 |
| 18 | Rachel K. King | Director | 5,119 | 0 | 5,119 | 0.0% | 02 Jan, 2024 |
| 19 | Patricia S Andrews | Director | 1,039 | 0 | 1,039 | 0.0% | 02 Jan, 2024 |
| 20 | Daniel M Junius | Director | 985 | 0 | 985 | 0.0% | 01 Apr, 2024 |
| 21 | Mark Alan Goldberg | Director | 451 | 0 | 451 | 0.0% | 01 Apr, 2024 |
| 22 | Scott Koenig | Director | 368 | 0 | 368 | 0.0% | 02 Jun, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 22 Jun, 2026 | Richard William Scalzo | Chief Financial Officer | Disposed S | 1,112 | $17.99 | $20.00K | 20,298 | Direct |
| 22 Jun, 2026 | Jonathan Mcneill | President And Coo | Disposed S | 20,549 | $17.99 | $369.68K | 139,158 | Direct |
| 22 Jun, 2026 | Jan Pinkas | Chief Scientific Officer | Disposed S | 1,288 | $17.99 | $23.17K | 22,239 | Direct |
| 22 Jun, 2026 | Ryan Lynch | Officer | Disposed S | 465 | $17.99 | $8.37K | 13,871 | Direct |
| 22 Jun, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Disposed S | 1,219 | $17.99 | $21.93K | 22,069 | Direct |
| 22 Jun, 2026 | Joshua T Brumm | Chief Executive Officer | Disposed S | 42,305 | $17.99 | $761.07K | 281,212 | Direct |
| 22 Jun, 2026 | Barbara Harlin Bispham | Officer | Disposed S | 1,218 | $17.99 | $21.91K | 19,330 | Direct |
| 02 Jun, 2026 | Alexandra Balcom | Director | Acquired A | 11,050 | $0.00 | $0 | 11,050 | Direct |
| 02 Jun, 2026 | Jonathan Violin | Director | Acquired A | 11,050 | $0.00 | $0 | 11,050 | Direct |
| 02 Jun, 2026 | Susan Moran | Director | Acquired A | 11,050 | $0.00 | $0 | 11,050 | Direct |
| 15 Dec, 2025 | Jonathan Mcneill | President And Coo | Acquired A | 19,507 | — | — | 153,707 | Direct |
| 15 Dec, 2025 | Ryan Lynch | Officer | Acquired A | 8,378 | — | — | 8,378 | Direct |
| 15 Dec, 2025 | Richard William Scalzo | Chief Financial Officer | Acquired A | 14,422 | — | — | 14,422 | Direct |
| 15 Dec, 2025 | Christopher Grant Doughty | Chief Business Officer | Acquired A | 14,714 | — | — | 54,194 | Direct |
| 15 Dec, 2025 | Richard William Scalzo | Chief Financial Officer | Acquired A | 14,422 | — | — | 14,422 | Direct |
| 15 Dec, 2025 | Jonathan Mcneill | President And Coo | Acquired A | 19,507 | — | — | 153,707 | Direct |
| 15 Dec, 2025 | Christopher Grant Doughty | Chief Business Officer | Acquired A | 14,714 | — | — | 54,194 | Direct |
| 15 Dec, 2025 | Jonathan Mcneill | President And Coo | Acquired A | 19,507 | — | — | 153,707 | Direct |
| 15 Dec, 2025 | Ryan Lynch | Officer | Acquired A | 8,378 | — | — | 8,378 | Direct |
| 15 Dec, 2025 | Ryan Lynch | Officer | Acquired A | 8,378 | — | — | 8,378 | Direct |